Kuznicki Law is
investigating the proposed sale of Satsuma Pharmaceuticals, Inc. (“Satsuma”) (NasdaqGM: STSA) to Shin Nippon Biomedical Laboratories, Ltd. Under the terms of the proposed transaction, shareholders of Satsuma will receive $0.91 in cash, plus one non-tradeable contingent value right (“CVR”) of up to $5.77 per share, for each share of Satsuma that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Please note that the merger is structured as a tender offer, such that time may be of the essence.